Seroepidemiology of pertussis immunity in five provinces of China: A population-based, cross-sectional study
Zhujiazi Zhang Qing Wang Qi Zhu Shuang Bai Yang Liu Jia Ren Xin Xu Jiangwen Qu Jingbin Pan Li Lu Luodan Suo Xiaodong Sun Ying Zhang Jiang Wu a Department of Immunization and Prevention,Beijing Center for Disease Prevention and Control,Beijing,Chinab Department of Immunization and Prevention,Chongqing Municipal Center for Disease Control and Prevention,Chongqing,Chinac Department of Immunization and Prevention,Guangdong Provincial Center for Disease Control and Prevention,Guangzhou,Chinad Department of Immunization and Prevention,Shanghai Municipal Center for Disease Control and Prevention,Shanghai,Chinae Department of Immunization and Prevention,Tianjin Center for Disease Control and Prevention,Tianjin,ChinaQing Wang Dr. Wang supervised data collection,carried out the initial analyses,interpreted results,drafted the manuscript,and approved the final manuscript as submitted.Qi Zhu Dr. Zhu carried out data collection and the initial analyses,and approved the final manuscript as submitted.Shuang Bai Dr. Bai tested laboratory samples and verified results,reviewed the manuscript,and approved the final manuscript as submitted.Yang Liu Dr. Liu carried out data collection and the initial analyses,and approved the final manuscript as submitted.Jia Ren Dr. Ren carried out data collection and the initial analyses,and approved the final manuscript as submitted.Xin Xu Dr. Xu carried out data collection and supervised data collection,reviewed,and revised the manuscript,and approved the final manuscript as submitted.Jiangwen Qu Dr. Qu carried out data collection and the initial analyses,and approved the final manuscript as submitted.Jingbin Pan Dr. Pan carried out data collection and the initial analyses,and approved the final manuscript as submitted.Li Lu Dr. Lu conceptualized the study,supervised data collection,reviewed and revised the manuscript,and approved the final manuscript as submitted.Luodan Suo Dr. Suo conceptualized the study,supervised data collection,reviewed and revised the manuscript,and approved the final manuscript as submitted.Xiaodong Sun Dr. Sun conceptualized the study,interpreted the results,reviewed and revised the manuscript,and approved the final manuscript as submitted.Zhujiazi Zhang Dr. Zhang conceptualized the study,supervised data collection,carried out the initial analyses,interpreted results,drafted the manuscript,and approved the final manuscript as submitted.Ying Zhang Dr. Zhang conceptualized the study,interpreted the results,reviewed and revised the manuscript,and approved the final manuscript as submitted.Jiang Wu Dr. Wu conceptualized the study,interpreted the results,reviewed and revised the manuscript,and approved the final manuscript as submitted.
DOI: https://doi.org/10.1080/21645515.2024.2417532
2024-11-19
Human Vaccines & Immunotherapeutics
Abstract:This study aimed to evaluate the seroprevalence of Bordetella pertussis and persistence of antibodies following vaccination. We recruited 6060 healthy subjects from five provinces of China during 2017–2018. Serum IgG antibodies against pertussis toxin (anti-PT IgG) and filamentous hemagglutinin (anti-FHA IgG), and serum IgA antibodies against pertussis toxin (anti-PT IgA) were measured by ELISA. Geometric mean concentration (GMC), seropositivity rate, and recent infection rate were calculated. Among 0–6 years-olds, the anti-PT IgG, anti-PT IgA, and anti-FHA IgG GMCs were 6.4 IU/ml (95% CI 6.1–6.8), 2.8 IU/ml (95% CI 2.7–2.8), and 13.3 IU/ml (95% CI 12.4–14.2), respectively. The anti-PT IgG GMC increased in accordance with the primary vaccination series (4–6 months) and the toddler booster (18–24 months), but declined thereafter through to age 5 years [4.7 IU/ml (95% CI 4.2–5.4)]. The seropositivity rate of pertussis in >6 year-olds was 9.0% (95% CI 8.1–9.9) and the recent infection rate was 3.3% (95% CI, 2.7–3.8). Recent infection rate began to increase from 6 years of age, with peaks at 9, 20, 40, and ≥60 years of age. The anti-PT IgG GMCs of children aged 0–6 years who were vaccinated with DTaP, DTaP-IPV//PRP~T, and DTaP-Hib were 5.9 IU/ml (95% CI 5.6–6.3), 20.7 IU/ml (95% CI 15.6–27.8), and 11.7 IU/ml (95% CI 7.5–18.1) ( p < .001), respectively ( p < .001). Pertussis vaccination improves anti-PT IgG levels, however these wane soon after vaccination. Sero-estimated recent infection rates appear to increase from school age into adolescence and adulthood. Pertussis vaccine boosters should be considered in these age groups.
immunology,biotechnology & applied microbiology